Valuation: Black Diamond Therapeutics, Inc.

Market Cap 11Cr 9.77Cr 9.2Cr 8.38Cr 16Cr 1.07TCr 16Cr 110.18Cr 42Cr 546.75Cr 42Cr 41Cr 1.76TCr P/E 2026 *
-3.16x
P/E 2027 * -2.05x
Enterprise Value 11Cr 9.77Cr 9.2Cr 8.38Cr 16Cr 1.07TCr 16Cr 110.18Cr 42Cr 546.75Cr 42Cr 41Cr 1.76TCr EV / Sales 2026 *
17.9x
EV / Sales 2027 * -
Free-Float
99.35%
Yield 2026 *
-
Yield 2027 * -
1 day+0.26%
1 week-0.25%
Current month-6.43%
1 month-8.82%
3 months+22.05%
6 months-8.60%
Current year-19.14%
1 week 1.9
Extreme 1.9
2.02
1 month 1.9
Extreme 1.9
2.32
Current year 1.6
Extreme 1.6
3.97
1 year 1.6
Extreme 1.6
4.94
3 years 1.2
Extreme 1.195
7.66
5 years 1.18
Extreme 1.18
9.99
10 years 1.18
Extreme 1.18
46.25
Manager TitleAgeSince
Chief Executive Officer 62 16/09/2023
Chief Tech/Sci/R&D Officer 51 11/08/2021
Director of Finance/CFO 41 07/10/2024
Director TitleAgeSince
Director/Board Member 61 01/03/2017
Director/Board Member 47 01/12/2019
Director/Board Member 49 01/12/2018
Date Insider Type Main position Quantity % Market Cap. Importance
20/03/26
NEA Management Co. LLC
OtherCompany 0 0% -
20/03/26 Free

Director

6,105 0.0107%
20/03/26 Free

Director

6,919 0.0121%
Change 5-day change 1-year change 3-year change Capi.($)
+0.26%-0.25%-42.54%-42.38% 11Cr
-0.07%+5.66%+54.34%+113.69% 7.43TCr
-1.45%-0.40%+35.52%+79.18% 6.23TCr
-0.66%+7.14%+39.36%+29.20% 2.77TCr
-0.73%+0.13%-17.20%+358.85% 2.64TCr
+3.30%+5.21%+3.04%-2.79% 2.46TCr
+0.84%+6.00%+25.53%-9.89% 2.07TCr
+0.87%-2.52%+151.81%+328.17% 1.5TCr
+2.51%+3.65%+49.00%+174.56% 1.42TCr
+1.89%-1.12%-9.92%+820.05% 1.35TCr
Average +0.64%+0.27%+28.89%+184.87% 2.79TCr
Weighted average by Cap. +0.12%+2.09%+37.03%+150.08%

Financials

2026 *2027 *
Net sales 62.5L 54.49L 51.32L 46.74L 87.63L 60Cr 87.74L 6.15Cr 2.37Cr 31Cr 2.35Cr 2.3Cr 98Cr -
Net income -3.7Cr -3.22Cr -3.04Cr -2.76Cr -5.18Cr -354.12Cr -5.19Cr -36Cr -14Cr -180.39Cr -14Cr -14Cr -582.1Cr -6.46Cr -5.64Cr -5.31Cr -4.83Cr -9.06Cr -619.35Cr -9.08Cr -64Cr -25Cr -315.5Cr -24Cr -24Cr -1.02TCr
Net Debt - -
Logo Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Employees
21
Date Price Change Volume
22/26/22 $1.935 -0.77% 3,23,783
21/26/21 $1.950 -0.51% 8,27,324
18/26/18 $1.960 +1.55% 11,78,623
17/26/17 $1.930 -0.52% 6,65,492
16/26/16 $1.940 -1.52% 7,33,907
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
1.950USD
Average target price
10.00USD
Spread / Average Target
+412.82%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BDTX Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!